Evidence map›Paper›PMID 15942875›Full record

ArticleAmerican journal of human genetics2005

Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations.

Katrina Tatton-Brown, Jenny Douglas, Kim Coleman, Genevieve Baujat, Trevor R P Cole, Soma Das, Denise Horn, Helen E Hughes, I Karen Temple, Francesca Faravelli and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 1 synthesis or guideline pooled it, 335 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Hyperinsulinemia in Sotos Syndrome with aJournal of clinical research in pediatric endocrinology · 2026
    Article
  9. Article
  10. Many faces of mammalian NSD methyltransferases.Cellular & molecular biology letters · 2026
    Review
  11. Article
  12. Article
  13. FamilialGenes · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 5 countries.

Katrina Tatton-BrownSection of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom.
Jenny Douglas
Kim Coleman
Genevieve Baujat
Trevor R P Cole
Soma Das
Denise Horn
Helen E Hughes
I Karen Temple
Francesca Faravelli
Darrel Waggoner
Seval Turkmen
Valerie Cormier-Daire
Alexandre Irrthum
Nazneen Rahman
Childhood Overgrowth Collaboration
Institute of Cancer Research · GBCharité - Universitätsmedizin Berlin · DEHôpital Necker-Enfants Malades · FRUniversity of Chicago · USBirmingham Women's Hospital · GBEnte Ospedaliero Ospedali Galliera · ITUniversity Hospital of Wales · GBUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

Medical Research Council G0400188
6 · The paper itself

Abstract

We identified 266 individuals with intragenic NSD1 mutations or 5q35 microdeletions encompassing NSD1 (referred to as "NSD1-positive individuals"), through analyses of 530 subjects with diverse phenotypes. Truncating NSD1 mutations occurred throughout the gene, but pathogenic missense mutations occurred only in functional domains (P < 2 x 10(-16)). Sotos syndrome was clinically diagnosed in 99% of NSD1-positive individuals, independent of the molecular analyses, indicating that NSD1 aberrations are essentially specific to this condition. Furthermore, our data suggest that 93% of patients who have been clinically diagnosed with Sotos syndrome have identifiable NSD1 abnormalities, of which 83% are intragenic mutations and 10% are 5q35 microdeletions. We reviewed the clinical phenotypes of 239 NSD1-positive individuals. Facial dysmorphism, learning disability, and childhood overgrowth were present in 90% of the individuals. However, both the height and head circumference of 10% of the individuals were within the normal range, indicating that overgrowth is not obligatory for the diagnosis of Sotos syndrome. A broad spectrum of associated clinical features was also present, the occurrence of which was largely independent of genotype, since individuals with identical mutations had different phenotypes. We compared the phenotypes of patients with intragenic NSD1 mutations with those of patients with 5q35 microdeletions. Patients with microdeletions had less-prominent overgrowth (P = .0003) and more-severe learning disability (P = 3 x 10(-9)) than patients with mutations. However, all features present in patients with microdeletions were also observed in patients with mutations, and there was no correlation between deletion size and the clinical phenotype, suggesting that the deletion of additional genes in patients with 5q35 microdeletions has little specific effect on phenotype. We identified only 13 familial cases. The reasons for the low vertical transmission rate are unclear, although familial cases were more likely than nonfamilial cases (P = .005) to carry missense mutations, suggesting that the underlying NSD1 mutational mechanism in Sotos syndrome may influence reproductive fitness.

Indexed as

Amino Acid SequenceChromosomes, Human, Pair 5ExonsFaciesFemaleFrameshift MutationGene DeletionGenotypeGrowth DisordersHistone-Lysine N-MethyltransferaseHistone MethyltransferasesHomozygoteHumansIntracellular Signaling Peptides and ProteinsLearning DisabilitiesMaleHistone-Lysine N-MethyltransferaseHistone MethyltransferasesIntracellular Signaling Peptides and ProteinsNSD1 protein, humanNuclear Proteins

Identifiers

PMID15942875
PMCPMC1224542
OpenAlexW2117902955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.